NCT03340506 2026-04-20Dabrafenib and/or Trametinib Rollover StudyNovartisPhase 4 Recruiting100 enrolled
NCT02465060 2026-04-13Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting6,452 enrolled 2 FDA
NCT03919071 2026-04-13Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade GliomaNational Cancer Institute (NCI)Phase 2 Active not recruiting58 enrolled
NCT03975829 2026-04-02Pediatric Long-Term Follow-up and Rollover StudyNovartisPhase 4 Active not recruiting163 enrolled